Back to List View Graph View

B cell maturation antigen (BCMA)

Tnf receptor superfamily member 17 (TNFRSF17), known as B-cell maturation antigen (BCMA), is a transmembrane receptor of the tumor necrosis factor receptor superfamily.

Where the papers sit

11 papers from the last 6 months study B cell maturation antigen (BCMA) directly · updated from PubMed 16 Nov 2026

Those 11 are all about one subject.

  • BCMA-Directed Immunotherapy

    BCMA-directed treatment is expanding across bispecific T-cell engagers, CAR-T therapy and engineered multispecific constructs for multiple myeloma. Teclistamab, elranatamab and ciltacabtagene autoleucel are being evaluated in earlier treatment lines and real-world sequencing, with durable responses balanced against safety concerns. Tirapazamine-loaded liposomes and affinity tuning seek to improve activity in hypoxic or heterogeneous disease. BCMA PET imaging and soluble-antigen assays are advancing disease detection and treatment monitoring, while applications beyond myeloma remain exploratory.

    11 papers

Papers

The 11 papers from the last 6 months that study B cell maturation antigen (BCMA) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BCMA-Directed Immunotherapy (11)
  1. B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma. Journal of controlled release : official journal of the Controlled Release Society · 15 Sept 2026 PMID 42744202
  2. Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
  3. Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy. Clinical lymphoma, myeloma & leukemia · 4 Jul 2026 PMID 42401497
  4. A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging. The Journal of clinical investigation · 30 Jun 2026 PMID 42378054
  5. Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy. Nature communications · 30 May 2026 PMID 42218153
  6. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
  7. Soluble-Antigen-Based PET/MR for the Specific Detection of BCMA CAR+ T-Cell Lymphoma. Molecular pharmaceutics · 28 May 2026 PMID 42207978
  8. Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
  9. Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Science translational medicine · 27 May 2026 PMID 42202046
  10. Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis. Journal of hematology & oncology · 21 May 2026 PMID 42163304
  11. Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. Cancer · 20 May 2026 PMID 42159085

By study type

Clinical trials (5)
  1. A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging. The Journal of clinical investigation · 30 Jun 2026 PMID 42378054
  2. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
  3. Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
  4. Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Science translational medicine · 27 May 2026 PMID 42202046
  5. Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. Cancer · 20 May 2026 PMID 42159085
Observational studies and case reports (2)
  1. Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy. Clinical lymphoma, myeloma & leukemia · 4 Jul 2026 PMID 42401497
  2. Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy. Nature communications · 30 May 2026 PMID 42218153
Preclinical: animal, cell and lab studies (3)
  1. B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma. Journal of controlled release : official journal of the Controlled Release Society · 15 Sept 2026 PMID 42744202
  2. Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
  3. Soluble-Antigen-Based PET/MR for the Specific Detection of BCMA CAR+ T-Cell Lymphoma. Molecular pharmaceutics · 28 May 2026 PMID 42207978
Unclassified: not yet indexed with MeSH (1)
  1. Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis. Journal of hematology & oncology · 21 May 2026 PMID 42163304